ProCE Banner Activity

From HIV Glasgow 2020, Less May Be More With the 2-Drug Regimen Dolutegravir/Lamivudine

Conference Coverage
Clinical Thought

New data from HIV Glasgow 2020 demonstrate the utility and durability of the 2-drug regimen DTG/3TC.

Released: November 06, 2020

Expiration: November 05, 2021

No longer available for credit.

Share

Faculty

Pedro Cahn

Pedro Cahn, MD, PhD

Scientific Director, Fundación Huésped
Former Professor of Infectious Disease
University of Buenos Aires
Past President
International AIDS Society
Buenos Aires, Argentina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Pedro Cahn, MD, PhD

Scientific Director, Fundación Huésped
Former Professor of Infectious Disease
University of Buenos Aires
Past President
International AIDS Society
Buenos Aires, Argentina

Pedro Cahn, MD, PhD, has disclosed that he has received funds for research support and consulting fees from Merck and ViiV and fees for non-CME/CE services from Gilead Sciences, Merck, and ViiV.